Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Systematic biopsy urged in patients with negative MRI

10 Oct 2020

Magnetic resonance imaging (MRI) is vital for the detection of high-grade cancer, and a recent study further adds to this data by recommending systematic biopsy in patients with negative MRI and the inclusion of systematic biopsy in those with positive MRI.

Men enrolled in Canary Prostate Active Surveillance Study with Gleason grade group <2 and who underwent biopsy within 12 months of multiparametric MRI were included in this analysis. Biopsy reclassification to Gleason grade group 2 was the primary outcome.

The authors assessed the performance of MRI Prostate Imaging–Reporting and Data System (PI-RADS) score and clinical factors. They also fitted multivariable logistic regression models with MRI and clinical factors and used these models to perform receiver operating curve analyses.

Overall, 361 participants with 395 prostate MRI studies, with a median follow-up of 4.1 years (interquartile range, 2.0-7.6), were included. One hundred eight (27 percent) biopsies demonstrated reclassification.

Defining positive MRI as PI-RADS 3-5, the negative and positive predictive values for detecting Gleason grade group 2 cancer was 83 percent (95 percent confidence interval [CI], 76–90) and 31 percent (95 percent CI, 26–37), respectively.

In a multivariable model, PI-RADS significantly correlated with reclassification (PI-RADS 5 vs 1 and 2; odds ratio, 2.71, 95 percent CI, 1.21–6.17; p=0.016), but it did not improve upon a model with only clinical factors (AUC, 0.768 vs 0.762).

In 194 fusion biopsies, higher grade cancer was detected in targeted cores in 21 instances (11 percent). On the other hand, 24 (13 percent) had higher grade cancer in the systematic cores.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).